Mayne Pharma Group (MYX)- BUY
MYX’s FY18 result came in ahead of market expectations at the earnings line, with the Company enjoying a
Analyst Research
Medical Technology
Analyst Research
Nanosonics Ltd (NAN) – NEUTRAL
Nanosonic (NAN) reported as expected FY18 results. Key results highlights were: (1) Total sales of $60.7m were down -10%
Analyst Research
Cochlear Ltd (COH) – NEUTRAL
At times, even though a Company may produce a strong result, if it does not meet the higher